AlphaTON Capital Corp is a clinical stage immuno oncology company focused on developing therapies that target resistance pathways in cancer. The company builds a pipeline of product candidates that include adenosine receptor antagonists and invariant natural killer T cell engagers. It seeks to create first in class treatments for solid tumors and hematologic malignancies. AlphaTON Capital Corp conducts research through collaborations with academic institutions and uses its internal expertise to advance candidates toward clinical testing.

AlphaTON Capital Corp does not yet generate revenue from product sales. The company finances its operations primarily through the sale of its ordinary shares in public offerings and at the market programs. It has used a shelf registration statement to raise proceeds for research and development activities and general corporate purposes.

AlphaTON Capital Corp operates in a highly competitive immuno oncology landscape that includes large pharmaceutical firms and specialized biotechnology companies. Its competitors include firms such as Cullinan Oncology PureTech Health Black Diamond Therapeutics Repare Therapeutics Nuvation Bio Shattuck Labs Arcus Biosciences Syndax Pharmaceuticals and iTeos Therapeutics. The company differentiates itself through a diversified pipeline that targets multiple resistance mechanisms and through relationships with academic partners like the University of Oxford Stanford University the National Cancer Institute Yale University and the Ludwig Institute. These collaborations provide access to early stage technologies and scientific expertise that larger peers may lack.

AlphaTON Capital Corp ultimately aims to serve patients with advanced cancers by providing therapies that could be administered in hospitals and oncology clinics. Its potential customers include healthcare providers treatment centers and individuals receiving cancer care. The company has not disclosed specific customer names in the filing.